Insight Molecular Diagnostics (IMDX) Cash from Financing Activities (2015 - 2026)
Insight Molecular Diagnostics (IMDX) posted Cash from Financing Activities of $24.7 million for Q1 2026, up 9900.79% sequentially from -$252000.0 in Q4 2025, and down 13.52% YoY from $28.6 million in Q1 2025.
Insight Molecular Diagnostics (IMDX) Cash from Financing Activities (2015 - 2026) Analysis & Trends
Insight Molecular Diagnostics has reported Cash from Financing Activities for 12 years, with the latest figure at $24.7 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 13.52% year-over-year to $24.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.2 million (down 50.57% YoY) and the FY2025 annual result came in at $28.1 million, up 37.41% from the prior year.
- Cash from Financing Activities climbed to $24.7 million in Q1 2026 per IMDX's latest filing, from -$252000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $36.8 million in Q2 2022 and troughed at -$528000.0 in Q3 2022.
- A 5-year average of $7.6 million and a median of -$30000.0 in 2023 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 36223.33% in 2024, down 750.0% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$100000.0 in 2022, then surged by 70.0% to -$30000.0 in 2023, then soared by 36223.33% to $10.8 million in 2024, then slumped by 102.33% to -$252000.0 in 2025, then surged by 9900.79% to $24.7 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $24.7 million, -$252000.0, and -$120000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | -1.57 Bn |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 7.27 Bn |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | 12.21 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | -144.00 Mn |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | -214.00 Mn |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | -325.19 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | -129.00 Mn |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | -317.75 Mn |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | -919.90 Mn |
| 10 | Insight Molecular Diagnostics | 158.03 Mn | 139.50 Mn | 157,000.00 | -564,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -564,000.00 |
| Jun 30, 2026 | -564,000.00 |
| Mar 31, 2026 | 24.70 Mn |
| Mar 31, 2026 | 24.70 Mn |
| Dec 31, 2025 | -252,000.00 |
| Dec 31, 2025 | -252,000.00 |
| Sep 30, 2025 | -120,000.00 |
| Sep 30, 2025 | -120,000.00 |
| Jun 30, 2025 | -114,000.00 |
| Jun 30, 2025 | -114,000.00 |
| Mar 31, 2025 | 28.56 Mn |
| Mar 31, 2025 | 28.56 Mn |
| Dec 31, 2024 | 10.84 Mn |
| Dec 31, 2024 | 10.84 Mn |
| Sep 30, 2024 | -255,000.00 |
| Sep 30, 2024 | -255,000.00 |
| Jun 30, 2024 | 9.85 Mn |
| Jun 30, 2024 | 9.85 Mn |
| Dec 31, 2023 | -30,000.00 |
| Dec 31, 2023 | -30,000.00 |